1
|
Fishman B, Bardugo A, Zloof Y, Bendor CD, Libruder C, Zucker I, Lutski M, Ram A, Hershkovitz Y, Orr O, Omer M, Furer A, Goldman A, Yaniv G, Tanne D, Derazne E, Tzur D, Afek A, Grossman E, Twig G. Adolescent Hypertension Is Associated With Stroke in Young Adulthood: A Nationwide Cohort of 1.9 Million Adolescents. Stroke 2023; 54:1531-1537. [PMID: 37139816 DOI: 10.1161/strokeaha.122.042100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
BACKGROUND Adult hypertension is a well-established risk factor for stroke in young adults (aged <55 years), and the effects are even more deleterious than at an older age. However, data are limited regarding the association between adolescent hypertension and the risk of stroke in young adulthood. METHODS A nationwide, retrospective cohort study of adolescents (aged 16-19 years) who were medically evaluated before compulsory military service in Israel during 1985 to 2013. For each candidate for service, hypertension was designated after constructed screening, and the diagnosis was confirmed through a comprehensive workup process. The primary outcome was ischemic and hemorrhagic stroke incidence as registered at the national stroke registry. Cox proportional-hazards models were used. We conducted sensitivity analyses by excluding people with a diabetes diagnosis at adolescence or a new diabetes diagnosis during the follow-up period, analysis of adolescents with overweight, and adolescents with baseline unimpaired health status. RESULTS The final sample included 1 900 384 adolescents (58% men; median age, 17.3 years). In total, 1474 (0.08%) incidences of stroke (1236 [84%] ischemic) were recorded, at a median age of 43 (interquartile range, 38-47) years. Of these, 18 (0.35%) occurred among the 5221 people with a history of adolescent hypertension. The latter population had a hazard ratio of 2.4 (95% CI, 1.5-3.9) for incident stroke after adjustment for body mass index and baseline sociodemographic factors. Further adjustment for diabetes status yielded a hazard ratio of 2.1 (1.3-3.5). We found similar results when the outcome was ischemic stroke with a hazard ratio of 2.0 (1.2-3.5). Sensitivity analyses for overall stroke, and ischemic stroke only, yielded consistent findings. CONCLUSIONS Adolescent hypertension is associated with an increased risk of stroke, particularly ischemic stroke, in young adulthood.
Collapse
Affiliation(s)
- Boris Fishman
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Division of Cardiology, Sheba Medical Center, Ramat Gan, Israel. (B.F., A.F.)
- The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel. (B.F., A.G., G.T.)
| | - Aya Bardugo
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Yair Zloof
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Cole D Bendor
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Carmit Libruder
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (C.L., I.Z., M.L., A.R., Y.H.)
| | - Inbar Zucker
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (C.L., I.Z., M.L., A.R., Y.H.)
| | - Miri Lutski
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (C.L., I.Z., M.L., A.R., Y.H.)
| | - Amit Ram
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (C.L., I.Z., M.L., A.R., Y.H.)
| | - Yael Hershkovitz
- Israel Center for Disease Control, Ministry of Health, Ramat Gan, Israel (C.L., I.Z., M.L., A.R., Y.H.)
| | - Omri Orr
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
- Orthopedic Surgery, Rambam Health Care Campus, Haifa, Israel (O.O.)
| | - Ma'ayan Omer
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Ariel Furer
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Division of Cardiology, Sheba Medical Center, Ramat Gan, Israel. (B.F., A.F.)
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Adam Goldman
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, Israel. (A.G., G.T.)
- The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel. (B.F., A.G., G.T.)
- Department of Medicine F, Sheba Medical Center, Ramat Gan, Israel. (A.G.)
| | - Gal Yaniv
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Department of Diagnostic Imaging, Sheba Medical Center, Ramat Gan, Israel. (G.Y.)
| | - David Tanne
- Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel (D. Tanne)
| | - Estela Derazne
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
| | - Dorit Tzur
- Department of Military Medicine, Hebrew University, Jerusalem and the Israel Defense Forces Medical Corps, Ramat Gan, Israel (A.B., Y.Z., C.D.B., O.O., M.O., A.F., D. Tzur)
| | - Arnon Afek
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Central Management, Sheba Medical Center, Ramat Gan, Israel. (A.A.)
| | - Ehud Grossman
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Hypertension Unit and the Internal Division, Sheba Medical Center, Ramat Gan, Israel. (E.G.)
| | - Gilad Twig
- Faculty of Medicine, Tel Aviv University, Israel. (B.F., Y.Z., I.Z., M.L., A.F., A.G., G.Y., E.D., A.A., E.G., G.T.)
- Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, Israel. (A.G., G.T.)
- The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan, Israel. (B.F., A.G., G.T.)
- Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Ramat Gan, Israel. (G.T.)
| |
Collapse
|
3
|
Omer M, Amir-Khalili A, Sojoudi A, Thao Le T, A Cook S, Faye Toh D, Bryant J, Chin C, Miguel Paiva J, Fung K, Aung N, Y Khanji M, Rauseo E, Cooper J, E Petersen S. Assessing automated CMR contouring algorithms using systematic contour quality scoring analysis. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): SmartHeart EPSRC programme grant (www.nihr.ac.uk), London Medical Imaging and AI Centre for Value-Based Healthcare
Background
Quality measures for machine learning algorithms include clinical measures such as end-diastolic (ED) and end-systolic (ES) volume, volumetric overlaps such as Dice similarity coefficient and surface distances such as Hausdorff distance. These measures capture differences between manually drawn and automated contours but fail to capture the trust of a clinician to an automatically generated contour.
Purpose
We propose to directly capture clinicians’ trust in a systematic way. We display manual and automated contours sequentially in random order and ask the clinicians to score the contour quality. We then perform statistical analysis for both sources of contours and stratify results based on contour type.
Data
The data selected for this experiment came from the National Health Center Singapore. It constitutes CMR scans from 313 patients with diverse pathologies including: healthy, dilated cardiomyopathy (DCM), hypertension (HTN), hypertrophic cardiomyopathy (HCM), ischemic heart disease (IHD), left ventricular non-compaction (LVNC), and myocarditis. Each study contains a short axis (SAX) stack, with ED and ES phases manually annotated. Automated contours are generated for each SAX image for which manual annotation is available. For this, a machine learning algorithm trained at Circle Cardiovascular Imaging Inc. is applied and the resulting predictions are saved to be displayed in the contour quality scoring (CQS) application.
Methods: The CQS application displays manual and automated contours in a random order and presents the user an option to assign a contour quality score
1: Unacceptable, 2: Bad, 3: Fair, 4: Good. The UK Biobank standard operating procedure is used for assessing the quality of the contoured images. Quality scores are assigned based on how the contour affects clinical outcomes. However, as images are presented independent of spatiotemporal context, contour quality is assessed based on how well the area of the delineated structure is approximated. Consequently, small contours and small deviations are rarely assigned a quality score of less than 2, as they are not clinically relevant. Special attention is given to the RV-endo contours as often, mostly in basal images, two separate contours appear. In such cases, a score of 3 is given if the two disjoint contours sufficiently encompass the underlying anatomy; otherwise they are scored as 2 or 1.
Results
A total of 50991 quality scores (24208 manual and 26783 automated) are generated by five expert raters. The mean score for all manual and automated contours are 3.77 ± 0.48 and 3.77 ± 0.52, respectively. The breakdown of mean quality scores by contour type is included in Fig. 1a while the distribution of quality scores for various raters are shown in Fig. 1b.
Conclusion
We proposed a method of comparing the quality of manual versus automated contouring methods. Results suggest similar statistics in quality scores for both sources of contours.
Abstract Figure 1
Collapse
Affiliation(s)
- M Omer
- Circle Cardiovascular Imaging Inc., Calgary, Canada
| | | | - A Sojoudi
- Circle Cardiovascular Imaging Inc., Calgary, Canada
| | - T Thao Le
- National Heart Centre Singapore, Singapore, Singapore
| | - S A Cook
- National Heart Centre Singapore, Singapore, Singapore
| | - D Faye Toh
- National Heart Centre Singapore, Singapore, Singapore
| | - J Bryant
- National Heart Centre Singapore, Singapore, Singapore
| | - C Chin
- National Heart Centre Singapore, Singapore, Singapore
| | | | - K Fung
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| | - N Aung
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| | - M Y Khanji
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| | - E Rauseo
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| | - J Cooper
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| | - S E Petersen
- Barts Heart Centre, London, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
7
|
Montes VN, Subramanian S, Goodspeed L, Wang SA, Omer M, Bobik A, Teshigawara K, Nishibori M, Chait A. Anti-HMGB1 antibody reduces weight gain in mice fed a high-fat diet. Nutr Diabetes 2015; 5:e161. [PMID: 26075638 PMCID: PMC4491852 DOI: 10.1038/nutd.2015.11] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 04/05/2015] [Accepted: 04/22/2015] [Indexed: 01/19/2023] Open
Abstract
Insulin resistance in obesity is believed to be propagated by adipose tissue and liver inflammation. HMGB1 is a multifunctional protein that is pro-inflammatory when released from cells. It has been previously demonstrated that anti-HMGB1 antibody reduces atherosclerotic lesion pro-inflammatory cells and progression of atherosclerosis in a mouse model. To test the potential beneficial role of blocking HMGB1 in adipose tissue and liver inflammation in mice fed an obesogenic diet, we administered anti-HMGB1 antibody to C57Bl/6 mice fed a high (60%)-fat diet. The mice were treated with weekly injections of an anti-HMGB1 antibody or anti-KLH antibody (isotype control) for 16 weeks. Mice that received the anti-HMGB1 antibody gained less weight than the control-treated animals. Anti-HMGB1 treatment also reduced hepatic expression of TNF-alpha and MCP-1, molecules that promote inflammation. However, adipose tissue inflammation, as measured by gene expression analyses and immunohistochemistry, did not differ between the two groups. There also were no differences in glucose or insulin tolerance between the two groups. When feeding mice a high-fat diet, these data suggest that HMGB1 may have a crucial role in weight gain and liver inflammation.
Collapse
Affiliation(s)
- V N Montes
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| | - S Subramanian
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| | - L Goodspeed
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| | - S A Wang
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| | - M Omer
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| | - A Bobik
- BakerIDI Heart and Diabetes Institute, Melbourne, Australia
| | - K Teshigawara
- Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
| | - M Nishibori
- Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
| | - A Chait
- Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
| |
Collapse
|